摘要
大麻中具有药用价值的主要成分是Δ9-四氢大麻酚(Δ9-THC)和大麻二酚(CBD),其中CBD因不能直接激活大麻素1型受体(CB1R)和大麻素2型受体(CB2R)而不具有精神活性和药物依赖性,安全性相对高。CBD作为主要的大麻素提取物,证实具有镇痛、镇静、抗炎、抗惊厥、改善睡眠、抗焦虑、抗精神病、抗风湿、保护皮肤屏障、抗细胞凋亡和神经保护等作用。本综述旨在总结CBD在临床疾病治疗中的应用现状,为今后CBD相关药物在治疗癫痫、神经病理性疼痛、焦虑症和抑郁症、肿瘤、皮肤、代谢相关疾病的应用提供新思路。
The main components of cannabis with medicinal value areΔ9-tetrahydrocannabinol(Δ9-THC)and cannabidiol(CBD),of which CBD cannot directly activate cannabinoid type 1 receptor(CB1R)and cannabinoid type 2 receptors.Body(CB2R)does not have psychoactive and drug dependence,and its safety is relatively high.CBD,as the main cannabinoid extract,has proven to have analgesic,sedative,anti-inflammatory,anticonvulsant,sleep-improving,anti-anxiety,anti-psychotic,anti-rheumatic,skin barrier,anti-apoptotic and neuroprotective effects.This review aims to summarize the application status of CBD in the treatment of clinical diseases,and provide new ideas for the future application of CBD-related drugs in the treatment of epilepsy,neuropathic pain,anxiety and depression,tumors,skin,and metabolism-related diseases.
作者
蒋鸿雁
张瑞林
曹艳
吴海鹰
李坪
JIANG Hong-yan;ZHANG Rui-lin;CAO Yan;WU Hai-ying;LI Ping(Dept.of Human Anatomy and Histology and Embryology,Kunming Medical University;Dept.of Toxicology,School of Forensic Medicine;Dept.of Emergency Medicine,First Affiliated Hospital,Kunming Yunnan 650032;Dept.of Pathology,Suining Central Hospital,Suining Sichuan,China)
出处
《昆明医科大学学报》
CAS
2021年第2期147-152,共6页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(82060241,82002002,81960817)
云南省科技创新团队基金资助项目(2019HC014)。
